Evidence map›Paper›PMID 41665356›Full record

ArticleMicrobiology spectrum2026

High

Eetu Eklund, Tyler Maruca, Kate Kruczynski, Heather Critchfield, Robert Murphy, Eric Keller, Benjamin Lee, Ami Patel, Liore Klein, David A Torpey and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eetu EklundMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Tyler MarucaMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Kate KruczynskiMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Heather CritchfieldMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Robert MurphyMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Eric KellerMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Benjamin LeeMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Ami PatelMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Liore KleinMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
David A TorpeyMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Robert A MyersMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.
Victoria L CampodónicoMaryland Department of Health Laboratories Administration, Baltimore, Maryland, USA.ORCID 0009-0006-7840-1199

Funding

Centers for Disease Control and Prevention Foundation CK19-1904, CK24-0002
6 · The paper itself

Abstract

New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales represent a critical antimicrobial resistance threat with limited therapeutic options. Aztreonam/avibactam, which combines the stability of aztreonam against metallo-β-lactamases with the inhibition of serine β-lactamases by avibactam, is a promising therapeutic candidate. However, emerging resistance associated with IMPORTANCE: The approval of aztreonam/avibactam provides a critical therapeutic option for treating infections caused by metallo-β-lactamase-producing Enterobacterales, including NDM-positive strains that are resistant to nearly all other β-lactams. However, emerging resistance due to PBP3 (

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesDrug Resistance, Multiple, BacterialEnterobacteriaceaeEscherichia coliEscherichia coli InfectionsHumansMicrobial Sensitivity TestsUnited StatesAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-Lactamasesaztreonam/avibactamEnterobacteralesNew Delhi metallo-β-lactamase (NDM)β-lactam/β-lactamase inhibitor combination

Identifiers

PMID41665356
PMCPMC12955408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.